TMB measured from liquid biopsy was also found to be a predictive biomarker for atezolizumab (anti-PD-L1) in NSCLC, and able to identify patients who would benefit accurately and reproducibly [239]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.